Section Arrow
ATYR.NASDAQ
- aTyr Pharma Inc
(Financial Status)
Quotes are at least 15-min delayed:2026/04/16 06:58 EDT
Pre Market
Last
 0.8645
+0.0218 (+2.59%)
Bid
0.851
Ask
0.8645
High 0.8645 
Low 0.851 
Volume 3.26K 
Regular Hours (Closed)
Last
 0.8427
+0.0018 (+0.21%)
Day High 
0.8724 
Prev. Close
0.8409 
1-M High
0.9098 
Volume 
1.06M 
Bid
0.851
Ask
0.8645
Day Low
0.8301 
Open
0.85 
1-M Low
0.72 
Market Cap 
82.45M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 0.81 
20-SMA 0.81 
50-SMA 0.88 
52-W High 7.2904 
52-W Low 0.64 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.80/-0.59
Enterprise Value
93.02M
Balance Sheet
Book Value Per Share
0.69
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
190.00K
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
IMMPImmutep Limited0.544+0.2292+72.81%-- 
Pre Market 0.562 +0.018 +3.31%
LIMNLiminatus Pharma Inc0.1856+0.0058+3.23%-- 
Pre Market 0.1856 0 0.00%
PPCBPropanc Biopharma Inc0.1106+0.0131+13.44%0PE
Pre Market 0.0956 -0.015 -13.56%
ALLOAllogene Therapeutics2.17-0.11-4.82%-- 
Pre Market 2.18 +0.01 +0.46%
CUECue Biopharma0.7243+0.2863+65.37%-- 
Pre Market 0.6367 -0.0876 -12.09%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.